128 results about "Gemcitabine" patented technology

The invention discloses a compound liposome, a freeze-dried powder injection as well as a preparation method and application of the freeze-dried powder injection. The compound lipidosome comprises a lipidosome membrane and an inner water phase encapsulated in the lipidosome membrane, the paclitaxel palmitate is encapsulated in a lipid bilayer of the liposome membrane; the gemcitabine or the salt thereof is encapsulated in the inner water phase; the compound liposome comprises the following raw materials: paclitaxel palmitate, lecithin, a polyethylene glycol derivative, gemcitabine or a salt thereof, an organic solvent and a buffer solution A; the molar ratio of the lecithin to the polyethylene glycol derivative is 1: (0.01-0.15). The compound liposome disclosed by the invention is relatively high in encapsulation efficiency (especially the encapsulation efficiency of PTX-PA is relatively good) and relatively high in safety, the preparation method is simple and easy to operate, the industrialization degree is high, and the prepared compound liposome has a relatively good long-circulation effect, a relatively good anti-tumor effect and good in-vivo tolerance.

The invention relates to the field of biology, and provides a human immortalized pancreatic cancer fibroblast as well as a preparation method and application thereof.The human immortalized pancreatic cancer fibroblast comprises three cell strains which are all primary fibroblast cells extracted from tumor tissues of pancreatic ductal adenocarcinoma patients, the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are classified and named as the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 respectively, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are all Cell STR identification and immunofluorescence detection prove that the cell strain is a fibroblast cell strain. After the tumor-associated fibroblast and pancreatic cancer cells are co-cultured, the proliferation ability of the tumor cells is obviously enhanced, and the sensitivity of the tumor cells to a chemotherapeutic drug gemcitabine is reduced. A new thought is provided for diagnosis and treatment of pancreatic cancer, and based on the pancreatic cancer in-vitro co-culture model established in vitro, the application has important significance for researching the effect and related mechanisms of fibroblasts in the pancreatic cancer tumor microenvironment.

Provided are siRNA compositions comprising gemcitabine (GEM) substituted for cytosine moieties in siRNAs. Provided are pharmaceutical compositions containing these siRNA molecules, and methods of using these compositions to treat diseases, such as cancer.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The application discloses a LYTAG-Gem compound for enhancing the anti-tumor effect of gemcitabine and application thereof, relates to the technical field of biological medicine, and particularly relates to a gemcitabine (Gem) targeted delivery system based on a lysosome targeting chimera (LYTAC) and application thereof in enhancing the anti-tumor process. 2+ The system is assembled from heavy chain ferritin, Ni 2+ , NTA-PEG5000-DBCO and a targeting ligand TPP-1-N3 in a specific mass percentage, can efficiently load Gem and form a nano compound with a particle size of about 59-79 nm, the system targets tumor cells through heavy chain ferritin, and realizes site-specific release of Gem in cells by means of an endocytosis-lysosome pathway mediated by the LYTAC structure, in-vivo pharmacodynamic experiments show that the LYTAC-Gem compound can significantly inhibit the tumor growth of a KPC pancreatic cancer mouse model, molecular mechanism research further reveals that the LYTAC-Gem compound can down-regulate the expression of PD-L1 protein in tumor tissues, and it is indicated that the LYTAC-Gem compound has the potential to activate an anti-tumor immune response, and the application provides a novel targeted delivery strategy for overcoming the toxic side effects and tumor drug resistance of gemcitabine.

The present invention provides methods for treatment of high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy by locally administering gemcitabine to the bladder. Also provided herein are kits and articles of manufacture for treating high-risk non-muscle invasive bladder cancer that is unresponsive to BCG.

The present disclosure concerns methods for treating pancreatic cancer cells with a combination of gemcitabine (GEM) and SapC-DOPS. In some aspects, GEM treatment preferentially targets G1 phase cells which are low in surface phosphatidylserine (PS), resulting in an increased median surface PS level of PDAC cells. Inversely, SapC-DOPS targets high surface PS cells which are predominantly in the G2 / M phase. In other aspects, a combination therapy on tumors in vivo with SapC-DOPS and GEM or Abraxane® (Abr) / GEM is demonstrated to significantly inhibit tumor growth and increases survival.

Provided include methods, compositions and kits for treating ovarian cancer (e.g., platinum-resistant ovarian cancer) in a subject. The method can comprise administration of a combination of a PLK1 inhibitor and a DNA-damaging agent (e.g., carboplatin or gemcitabine) to the subject in a manner sufficient to inhibit progression of the cancer.

The present disclosure provides double stranded nucleic acid compositions incorporating uracil, gemcitabine, and methotrexate (MTX). More specifically, the present disclosure reveals that modification of a double-stranded microRNA nucleotide sequence with 5-fluorouracil, gemcitabine, and methotrexate (MTX) enhances the therapeutic efficacy and tumor specificity of tumor suppression. Thus, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-fluorouracil, gemcitabine, and methotrexate (MTX) incorporated into their nucleic acid sequences, as well as methods of using the same. The disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancer, e.g., pancreatic cancer. The method is a platform technology which can be applied to other tumor suppressor genes miRNA and siRNA.

The invention provides a drug-loaded gelatin nanogel, a bionic nanogel, a preparation method of the drug-loaded gelatin nanogel, a preparation method of the bionic nanogel, a combined drug and application of the bionic nanogel, and belongs to the technical field of biological medicine. According to the invention, all-transretinoic acid, pirfenidone and gelatin react to form drug-loaded gelatin nanogel, and the drug-loaded gelatin nanogel can synergistically inhibit the activation of pancreatic stellate cells and block a fibrosis-promoting signal channel, so that the reversion of a pancreatic cancer fibrosis microenvironment is realized; meanwhile, the activated pancreatic stellate cell membrane is coated with the drug-loaded gelatin nanogel to construct the bionic nanogel, so that the bionic nanogel has active targeting property, and the delivery efficiency and the treatment effect of the drug are remarkably improved; and the drug-loaded gelatin nanogel, the bionic nanogel and the chemotherapeutic drug are combined for treating pancreatic cancer, so that a remarkable anti-tumor effect is achieved, and the combined treatment of the bionic nanogel and gemcitabine has a synergistic anti-tumor effect. The gel provided by the invention realizes effective regulation and control of a pancreatic cancer dense fibrosis microenvironment, and provides a feasible new strategy for treatment of pancreatic cancer.

The invention relates to a gemcitabine prodrug nano assembly as well as a preparation method and application thereof, and belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations. The gemcitabine-vitamin E prodrug is obtained by connecting gemcitabine and vitamin E by taking thiodiglycolic anhydride as a connecting chain, and the specific structure is as shown in a general formula (I). The prodrug disclosed by the invention can construct and form a gemcitabine-vitamin E prodrug nano assembly with good self-assembly stability and chemical stability based on a Core-matured technology, and specifically releases gemcitabine in a high-oxidation environment in tumor cells, so that the curative effect of gemcitabine is effectively improved, the toxic and side effects of gemcitabine are reduced, and the preparation method is suitable for clinical application. And a new strategy and choice are provided for developing a high-efficiency and low-toxicity chemotherapy preparation.

The present invention is directed to polymer-drug conjugates and / or compositions and / or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and / or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and / or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.

The present invention provides methods, devices and kits relating to treating lower tract urothelial carcinomas with an antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treating lower tract urothelial carcinomas with an antimetabolite (such as gemcitabine) and an immunomodulatory agent.

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

The invention provides a pharmaceutical composition for preventing and / or treating pancreatic cancer and application, and belongs to the technical field of biological medicine. According to the pharmaceutical composition, through combination of amentotaxus biflavone and gemcitabine, the prevention and treatment effect of gemcitabine or amentotaxus biflavone on pancreatic cancer can be further improved, and the pharmaceutical composition has a synergistic interaction effect. Research results show that the combination of amentoflavone and gemcitabine not only can significantly inhibit the growth of pancreatic cancer cells, but also can inhibit the migration ability of pancreatic cancer cells. The pharmaceutical composition disclosed by the invention provides more choices for clinically preventing and treating pancreatic cancer.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The application provides a candidate drug for promoting embryo implantation efficiency of a patient with endometrial microcirculation disorder type RIF, and belongs to the technical field of embryo implantation. In order to solve the problem of how to find a potential intervention drug for the pathological mechanism of microcirculation disorder type RIF, a five-step high-efficiency drug screening strategy based on an in-vitro implantation model of endometrial microcirculation disorder type repeated embryo implantation failure is adopted to ensure the reliability and functional correlation of the screening result. The candidate drug screened by the five-step high-efficiency drug screening strategy includes any one of the following drugs: phenylbutazone, ferulic acid, L-proline, indinavir, solfazone, teneligliptin and gemcitabine. Among the candidate drugs, phenylbutazone, ferulic acid and L-proline are the best three drugs for promoting the implantation efficiency of the patient with endometrial microcirculation disorder type RIF.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The application belongs to the technical field of nano drug loading, and particularly relates to an acid response drug delivery nanoparticle suitable for pancreatic cancer and a preparation method. The polyphenol polymer is a polymer with a biodegradable polyethylene glycol (PEG) polyphenol as a skeleton, and then a metal ion chelation effect is used to load a hydrophobic drug, improved gemcitabine and leflunomide, to form a nanoparticle. The nanoparticle can release the improved gemcitabine and leflunomide in response to a special environment in tumor cells, can regulate mitochondrial metabolism of pancreatic tumor cells, induce cell ferroptosis, and at the same time, the nanoparticle can induce mitochondrial exocytosis to realize deep drug accumulation, regulate an immune-metabolic network of multiple cells in a tumor lesion tissue, relieve an immunosuppressive microenvironment, and inhibit pancreatic tumors.

The present invention belongs to the technical field of cancer pharmaceuticals, and specifically relates to the use of AZD1152 and gemcitabine in the preparation of a drug for treating cholangiocarcinoma. AZD1152 and gemcitabine exhibit a synergistic effect in the treatment of cholangiocarcinoma. The combination of AZD1152 with gemcitabine can significantly inhibit cholangiocarcinoma cell proliferation and tumor growth, with efficacy superior to that of AZD1152 or gemcitabine alone.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention discloses a pharmaceutical composition for inhibiting tumor drug resistance and application thereof. The pharmaceutical composition comprises an exosome inhibitor, nintedanib and gemcitabine, the exosome inhibitor, the nintedanib and the gemcitabine are used in a combined manner, so that the cell viability of the CTS can be remarkably reduced, and the proportion of apoptotic cells in the CTS can be remarkably increased; the pharmaceutical composition interferes with the mutual transformation process between normal fibroblasts and CAFs, and inhibits secretion and release of EVs and reduces formation of new CAFs while restoring the CAFs existing in TME to normal fibroblasts, thereby successfully reversing the drug resistance of tumors.

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.

This invention relates to a liposomal formulation based on myeloid cell regulation and chemotherapy enhancement, along with its preparation method and antitumor applications, belonging to the technical field of pharmaceutical formulations. The liposomal formulation uses liposomes as carriers to co-load the CD11b agonist leukadherin-1 (LA1) prodrug (DSPE-PEG2000-Azo-LA1) and the gemcitabine prodrug Gem-SS-Chol. DSPE-PEG2000-Azo-LA1 contains a hypoxia-responsive azobenzene linker, and Gem-SS-Chol contains a glutathione-responsive disulfide bond, enabling precise drug release within the tumor microenvironment. This formulation exhibits uniform particle size and good stability, synergistically exerting chemotherapeutic and immunomodulatory effects. It effectively inhibits the proliferation and migration of pancreatic cancer tumor cells, enhances tumor cell immunogenic cell death, regulates the phenotype of myeloid immune cells in the tumor immunosuppressive microenvironment, and improves the therapeutic effect of pancreatic cancer. This invention provides a novel and highly efficient liposomal formulation for pancreatic cancer treatment, focusing on myeloid cell regulation and chemotherapy enhancement.

The present invention relates to methods for the treatment of T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and / or oxaliplatin. The treatments are particularly useful in the treatment of peripheral T cell lymphomas, for example PTCL-NOS.

The invention discloses a preparation method and application of a multistage rocket structure nanometer material in the technical field of biomedical materials. Mesoporous silicon dioxide (MSNs) serves as a core, gemcitabine (GEM) is wrapped in the core, the outer layer of the core is coated with calcium carbonate to form a middle layer, halofuginone (HF) is loaded on the middle layer, and the outermost layer is connected with targeting molecules to form a core-shell structure; the nano material has pH and GSH dual responsiveness, calcium carbonate on the outer layer is disintegrated in a subacid environment with the pH being 6.2-6.5, and mesoporous silica (MSNs) on the inner layer is further disintegrated in a 10mM GSH environment; the synthesis method provided by the invention is simple and easy to operate, and the nanoparticles have the advantages of large specific surface area, uniform particle size, good biocompatibility and the like.

The present invention provides CIP3M, a SN38 / gemcitabine conjugate that is useful as an anti-cancer agent. The present invention also provides pharmaceutical composition comprising CIP3M, and the use of CIP3M and pharmaceutical compositions thereof, as therapeutic agents, in particular in the treatment of cancers, including metastatic cancers and chemoresistant cancers.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

To provide: novel small molecule-drug conjugates (SMDCs) for using in the treatment or prevention of cancer or other proliferative conditions characterized by cells expressing cytochrome P4501B1 (CYP1B1) and allelic variants thereof; pharmaceutical compositions comprising one or more such compounds for use in the treatment or prevention of cancer or other proliferative conditions in medical therapy; and methods for treating cancer or other conditions in human or non-human patients.SOLUTION: Compounds of formula (I) are provided.SELECTED DRAWING: Figure 1a

This invention belongs to the field of ovarian cancer cell inhibitor technology, specifically relating to a reagent for inhibiting the proliferation of ovarian cancer cells, its preparation method, and its application. The reagent for inhibiting the proliferation of ovarian cancer cells is composed of the following raw materials: gemcitabine, vitamin B6, and a decoction of *Rhizophora stylosa* leaves, with a mass ratio of 0.4~0.7:5~10:1000. This invention utilizes vitamin B6 and *Rhizophora stylosa* leaf decoction to enhance the inhibitory effect of gemcitabine on ovarian cancer cells, showing significant killing effects on OVCAR3 and ES-2 cells, while exhibiting weak killing effects on normal human ovarian epithelial cells IOSE-80, suggesting that the reagent of this invention has anti-ovarian cancer activity.